Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients

Journal of Lipid Research

Volumn 44, Issue 6, 2003, Pages 1192-1198

  Parhofer, Klaus G ^a   Laubach, Ester ^a   Barrett, P Hugh R ^b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chylomicron remnants; Chylomicrons; Retinyl palmitate; Triglyceride rich lipoprotein

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; ATORVASTATIN; CHOLESTEROL; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL PALMITATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; ISOLATION PROCEDURE; LIPOPROTEIN METABOLISM; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULTRACENTRIFUGATION;

ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; BLOOD FLOW VELOCITY; CHOLESTEROL; HEPTANOIC ACIDS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; POSTPRANDIAL PERIOD; PYRROLES; TRIGLYCERIDES; VITAMIN A;

EID: 0142042354     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300011-JLR200     Document Type: Article

References (37)

1. Beckman, J. A., M. A. Creager, and P. Libby. 2002. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA. 287: 2570-2581.
2. Sacks, F. M., A. M. Tonkin, J. Shepherd, E. Braunwald, S. Cobbe, C. M. Hawkins, A. Keech, C. Packard, J. Simes, R. Byington, and C. D. Furberg. 2000. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 102: 1893-1900.
3. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: results of a randomized placebo-controlled trial. Lancet. 360: 7-22.
4. Chan, D. C., G. F. Watts, P. H. R. Barrett, L. J. Beilin, T. G. Redgrave, and T. A. Mori. 2002. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 51: 2377-2386.
5. Dane-Stewart, C. A., G. F. Watts, J. C. Mamo, S. B. Dimmitt, P. H. R. Barrett, and T. G. Redgrave. 2001. Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. Eur. J. Clin. Invest. 31: 113-117.
6. Björkergren, J., C. J. Packard, A. Hamsten, D. Bedford, M. Caslake, L. Foster, J. Shepherd, P. Stewart, and F. Karpe. 1996. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J. Lipid Res. 37: 76-86.
7. Cooper, A. D. 1997. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38: 2173-2192.
8. Kugiyama, K., H. Doi, K. Takazoe, H. Kawano, H. Soejima, Y. Mizuno, R. Tsunoda, T. Sakamoto, T. Nakano, K. Nakajima, H. Ogawa, S. Sugiyama, M. Yoshimura, and H. Yasue. 1999. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 99: 2858-2860.
9. Hodis, H. N., W. J. Mack, S. P. Azen, P. Alaupovic, J. M. Pogoda, L. LaBree, L. C. Hemphill, D. M. Kramsch, and D. H. Blankenhorn. 1994. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90: 42-49.
10. Karpe, F., G. Steiner, K. Uffelmann, T. Olivercrona, and A. Hamsten. 1994. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 106: 83-97.
11. Ginsberg, H. N., J. Jones, W. S. Blaner, A. Thomas, W. Karmally, L. Fields, D. Blood, and M. D. Begg. 1995. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler. Thromb. Vasc. Biol. 15: 1829-1838.
12. Boquist, S., G. Ruotolo, R. Tang, J. Bjorkegren, M. G. Bond, U. de Faire, F. Karpe, and A. Hamsten. 1999. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation. 100: 723-728.
13. Parhofer, K. G., P. H. R. Barrett, and P. Schwandt. 2000. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects. J. Clin. Endo. Metab. 85: 4224-4230.
14. Vansant, G., A. Mertens, and E. Muls. 2001. The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3. Acta Cardiol. 56: 149-154.
15. Guerin, M., P. Egger, W. Le Goff, C. Soudant, R. Dupuis, and M. J. Chapman. 2002. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J. Clin. Endocrinol. Metab. 7: 4991-5000.
16. Nordoy, A., J. B. Hansen, J. Brox, and B. Svensson. 2001. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr. Metab. Cardiovasc. Dis. 11: 7-16.
17. Schaefer, E. J., J. R. McNamara, T. Tayler, J. A. Daly, J. A. Gleason, L. J. Seman, A. Ferrari, and J. J. Rubenstein. 2002. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am. J. Cardiol. 90: 689-696.
18. Boquist, S., F. Karpe, K. Danell-Toverud, and A. Hamsten. 2002. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. Atherosclerosis. 162: 163-170.
19. Weintraub, M. S., S. Eisenberg, and J. L. Breslow. 1987. Different patterns of postprandial lipoprotein metabolism in normal, Type IIa, Type III, and Type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J. Clin. Invest. 79: 1110-1119.
20. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227: 680-685.
21. DeRuyter, M. G., and A. P. DeLeenheer. 1978. Simultaneous determination of retinol and retinyl esters in serum or plasma by reversed-phase high performance liquid chromatography. Clin. Chem. 24: 1920-1923.
22. Jones, P., S. Kafonek, I. Laurora, and D. Hunninghake, for the CURVES Investigators. 1998. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am. J. Cardiol. 81: 582-587.
23. The Diabetes Atorvastin Lipid Intervention (DALI) Study Group. 2001. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diab. Care. 24: 1335-1341.
24. Burnett, J. R., L. T. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. Barrett, R. S. Newton, and M. W. Huff. 1997. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apoB production in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 17: 2589-2600.
25. Wilcox, L. J., P. H. R. Barrett, and M. W. Huff. 1999. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J. Lipid Res. 40: 1078-1089.
26. Schoonjans, K., J. Peinado-Onsurbe, J. C. Fruchart, A. Tailleux, C. Fiévet, and J. Auwerx. 1999. HMGCoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein G-III and LPL. FEBS Lett. 452: 160-164.
27. Windler, E., and R. J. Havel. 1984. Inhibitory effects of C apoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by perfused rat liver. J. Lipid Res. 26: 556-565.
28. Kobayashi, J., T. Maruyama, M. Masuda, and M. Shinomiya. 2001. Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin. Chim. Acta. 314: 261-264.
29. Schneider, J., M. Henkels, D. Ramacher, and K. A. Dugi. 2002. Atorvastatin therapy ameliorates dyslipidemia by increasing lipoprotein lipase activity. Diabetes. 52(Suppl. 2): 587.
30. Weintraub, M. S., S. Eisenberg, and J. L. Breslow. 1989. Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia. Eur. J. Clin. Invest. 19: 480-485.
31. Cabezas, M. C., T. W. de Bruin, L. A. Kock, W. Kortlandt, M. Van Linde-Sibenius Trip, H. Jansen, and D. W. Erkelens. 1993. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism. 42: 497-503.
32. O'Keefe, J. H., W. S. Harris, J. Nelson, and S. L. Windsor. 1995. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am. J. Cardiol. 76: 480-484.
33. Simo, I. E., J. A. Yakichuk, and T. C. Ooi. 1993. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis. 100: 55-64.
34. Bhatnagar, D., P. N. Durrington, S. Kumar, M. I. Mackness, J. Dean, and A. J. Boulton. 1995. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes. 44: 460-465.
35. Twickler, T. B., G. M. Dallinga-Thie, H. W. de Valk, P. C. Schreuder, H. Jansen, M. C. Cabezas, and D. W. Erkelens. 2000. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 11: 2422-2427.
36. Burnett, J. R., P. H. Barrett, P. Vicini, D. B. Miller, D. E. Telford, S. J. Kleinstiver, and M. W. Huff. 1998. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 18: 1906-1914.
37. Pal, S., E. Allister, A. Thomson, and J. C. Mamo. 2002. Cholesterol esters regulate apoB48 secretion in CaCo2 cells. Atherosclerosis. 161: 55-63.